ClinicalTrials.gg
CompletedNCT02132169Updated Sep 11, 2017Results posted

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

A Phase 3 interventional study of Drug: AC-170 0.24% and AC-170 0% in Atopic Disease (Including Allergic Conjunctivitis), sponsored by Aciex Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2017-09-11.

Sponsored by Aciex Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
512
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.

Enrollment
5th of 90
512 · median 94
Started
2014
with 1 other
Phase 3
34 of 95
2 open now
Registered
60th of 95
by date
Lead sponsor
6 of 95
Aciex Therapeutics, Inc.

Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 5th largest by enrollment of the 90 interventional ones that give a count, is one of 2 that started in 2014, is one of 34 in phase 3, and was the 60th registered.

Conjunctivitis, Allergic

211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.

Browse Conjunctivitis, Allergic studies →

Open to participants now

6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Conjunctivitis, Allergic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).

03

Conditions studied

  • Atopic Disease (Including Allergic Conjunctivitis)
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 2 years of age
  • be able to self-administer eye drops or have a parent/legal guardian available for this purpose
  • if less than 18 years old have a history or family history of atopic disease (including allergic conjunctivitis)
  • have ocular health within normal limits

Exclusion criteria

Exclusion Criteria:

  • known or sensitivities to the study medication or its components
  • any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters
  • use of disallowed medication during the period indicated prior to the enrollment or during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
512 participants (actual)

Study arms

  • Experimental
    AC-170 0.24%

    Drug: Drug: AC-170 0.24%

  • Placebo comparator
    AC-170 0%

    Drug: AC-170 0%

Interventions

  • Also known as: 1 drop in each eye 2 times daily for up to 6 weeks

  • DrugAC-170 0%

    Also known as: 1 drop in each eye 2 times daily for up to 6 weeks

06

What researchers measure

Primary outcomes

  1. Tolerability of AC 170 0.24% Compared to Its Vehicle at Visit 1 (Day 1)

    Tolerability was assessed upon instillation of study medication, at 30 seconds and 1 minute post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.

    Time frame: Upon instillation, 30 Seconds Post-Instillation, 1 minute Post-Instillation

  2. Tolerability of AC 170 0.24% Compared to Its Vehicle at Visit 2 (Day 8)

    Tolerability was assessed upon instillation of study medication, at 30 seconds and 1 minute post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.

    Time frame: Upon instillation, 30 Seconds Post-Instillation, 1 minute Post-Instillation

  3. Tolerability of AC 170 0.24% Compared to Its Vehicle at Visit 3 (Day 22)

    Tolerability was assessed upon instillation of study medication, at 30 seconds and 1 minute post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.

    Time frame: Upon instillation, 30 Seconds Post-Instillation, 1 minute Post-Instillation

Secondary outcomes

  1. Safety of AC 170 0.024% Compared to Its Vehicle

    Safety measures (adverse events) of AC 170 0.024% compared to its vehicle were measured at Visit 1-4 and 5 (for subset of patients).

    Time frame: Up to 12 Weeks

07

Results

Posted Jul 26, 2017

Participant flow

Subjects were recruited from four sites in the US.

Participant flow — Overall Study
MilestoneAC-170 0.24%AC-170 0%
Started341171
Completed326162
Not completed159

Outcome measures

PrimaryTolerability of AC 170 0.24% Compared to Its Vehicle at Visit 1 (Day 1)

Tolerability was assessed upon instillation of study medication, at 30 seconds and 1 minute post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.

Time frame:
Upon instillation, 30 Seconds Post-Instillation, 1 minute Post-Instillation
Reported as:
Mean · units on a scale
Tolerability of AC 170 0.24% Compared to Its Vehicle at Visit 1 (Day 1)
units on a scaleAC-170 0.24%AC-170 0%
Upon instillation0.9 ± 1.360.5 ± 1.02
30 seconds post-instillation0.7 ± 1.250.3 ± 0.82
1 minute post-instillation0.6 ± 1.220.3 ± 0.75
PrimaryTolerability of AC 170 0.24% Compared to Its Vehicle at Visit 2 (Day 8)

Tolerability was assessed upon instillation of study medication, at 30 seconds and 1 minute post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.

Time frame:
Upon instillation, 30 Seconds Post-Instillation, 1 minute Post-Instillation
Reported as:
Mean · units on a scale
Tolerability of AC 170 0.24% Compared to Its Vehicle at Visit 2 (Day 8)
units on a scaleAC-170 0.24%AC-170 0%
Upon instillation0.8 ± 1.240.3 ± 0.80
30 seconds post-instillation0.5 ± 1.020.3 ± 0.74
1 minute post-instillation0.4 ± 0.900.2 ± 0.63
PrimaryTolerability of AC 170 0.24% Compared to Its Vehicle at Visit 3 (Day 22)

Tolerability was assessed upon instillation of study medication, at 30 seconds and 1 minute post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.

Time frame:
Upon instillation, 30 Seconds Post-Instillation, 1 minute Post-Instillation
Reported as:
Mean · units on a scale
Tolerability of AC 170 0.24% Compared to Its Vehicle at Visit 3 (Day 22)
units on a scaleAC-170 0.24%AC-170 0%
Upon instillation0.6 ± 1.130.2 ± 0.66
30 seconds post-instillation0.4 ± 0.830.2 ± 0.51
1 minute post-instillation0.3 ± 0.800.1 ± 0.47
SecondarySafety of AC 170 0.024% Compared to Its Vehicle

Safety measures (adverse events) of AC 170 0.024% compared to its vehicle were measured at Visit 1-4 and 5 (for subset of patients).

Time frame:
Up to 12 Weeks
Reported as:
Number · adverse events
Safety of AC 170 0.024% Compared to Its Vehicle
adverse eventsAC-170 0.24%AC-170 0%
Safety of AC 170 0.024% Compared to Its Vehicle7040

Adverse events

Collected over Adverse events were collected for the duration of the study. All subjects who received study medication were evaluable for the safety analysis.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AC-170 0.24%—1/341 (0.3%)65/341 (19.1%)
AC-170 0%—1/171 (0.6%)39/171 (22.8%)
Most frequent serious events
Most frequent serious events
EventAC-170 0.24%AC-170 0%
Anaphylactic shockImmune system disorders0/3411/171
Herpes zosterInfections and infestations1/3410/171
Most frequent other events
Most frequent other events
EventAC-170 0.24%AC-170 0%
Conjunctival HyperaemiaEye disorders27/34119/171
Instillation Site PainGeneral disorders20/3413/171
Ocular HyperaemiaEye disorders10/3413/171
Vision BlurredEye disorders2/3413/171
Dry eyeEye disorders1/3413/171
Visual acuity reducedEye disorders2/3412/171
Eye dischargeEye disorders1/3412/171
HeadacheNervous system disorders2/3412/171
DizzinessNervous system disorders0/3412/171

Baseline characteristics

Age, Continuous
Age, Continuous(years)AC-170 0.24%AC-170 0%Total
Mean34.9 ± 19.3636.6 ± 19.5635.4 ± 19.42
Age, Customized
Age, Customized(participants)AC-170 0.24%AC-170 0%Total
2-6 years old201333
7-12 years old281240
13-17 years old341650
>/= 18 years old259130389
Sex: Female, Male
Sex: Female, Male(Participants)AC-170 0.24%AC-170 0%Total
Female195114309
Male14657203
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AC-170 0.24%AC-170 0%Total
Hispanic or Latino201131
Not Hispanic or Latino321160481
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AC-170 0.24%AC-170 0%Total
American Indian or Alaska Native325
Asian325
Native Hawaiian or Other Pacific Islander000
Black or African American231437
White298149447
More than one race000
Unknown or Not Reported14418
Region of Enrollment
Region of Enrollment(participants)AC-170 0.24%AC-170 0%Total
United States341171512
08

Study locations

1 site
  • Ora, Inc.
    Andover, Massachusetts 01810, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 2 years 9 months after primary completion. A results delay was requested in Apr 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2014
First posted
May 7, 2014
Start
May 2014
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results delay requested
Apr 30, 2015
Results first posted
Jul 26, 2017
Last update
Sep 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02132169
Lead sponsor
Aciex Therapeutics, Inc.
Responsible party
Sponsor
First posted
May 7, 2014
Start date
May 2014
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Jul 26, 2017
Last update
Sep 11, 2017

Study contacts

Stacey L Ackerman, MD
principal investigator · Philadelphia Eye Associates
Dawn K De Castro, MD
principal investigator · Andover Eye Associates
Edward J Meier, MD
principal investigator · Apex Eye
Eugene E Protzko, MD
principal investigator · Seidenberg Protzko Eye Associates

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetirizine

Start the discussion